News

The European Lead Factory (ELF) offers a pharmacological strategy to aid in the discovery of new candidate molecules against SARS-CoV-2 causing COVID-19. The strategy is tailored to the needs of academic teams or SMEs in Europe and removes two important roadblocks: access to unique, novel, drug-like chemical starting points and the search for a feasible economic model to develop antiviral molecules.

Registration is now open for the second in a series of webinars hosted by the European Lead Factory (ELF).

Phenotypic screening is a powerful approach to identifying novel chemical starting points for drug discovery, offering the potential to uncover new drug targets and pathways underpinning disease-related biology. High Content Screening (HCS) is one of the phenotypic screening approaches offered by the European Lead Factory (ELF). To find out more about HCS and all it entails, we spoke to Professor Jason Swedlow, head of the National Phenotypic Screening Centre (NPSC) at the University of Dundee – one of ELF’s academic partners.

COVID-19 has led to in-person events being suspended or cancelled. In an effort to keep the European Lead Factory (ELF) community connected and informed of ongoing activities, we are pleased to announce that we will be organising a series of webinars on different programmes and topics within the ELF portfolio.